Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Allarity Therapeutics, Inc. - Common stock
(NQ:
ALLR
)
1.200
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Allarity Therapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
Next >
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
November 14, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
September 22, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
September 17, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Power Metallic’s (TSX-V: PNPN | OTCQB: PNPNF) Strategic Appointment Signals Major Paradigm Shift Ahead – More Stocks Inside
August 26, 2025
Via
AB Newswire
Topics
Government
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
August 26, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
August 15, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
July 15, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
July 07, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
June 30, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
June 27, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Changes to Board of Directors
June 11, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
June 04, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
June 02, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
May 12, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
May 09, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
April 25, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
March 31, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
March 24, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
March 17, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
March 13, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
March 06, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
March 03, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
February 26, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
February 24, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
February 06, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
January 30, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
November 18, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
November 14, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
November 12, 2024
From
The Schall Law Firm
Via
Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
November 12, 2024
From
Faruqi & Faruqi, LLP
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
